Hepatitis C - Annual Epidemiological Report for 2016
In 2016, 33 860 cases of hepatitis C were reported in 29 EU/EEA Member States, corresponding to a crude rate of 7.4 cases per 100 000 population.
Hepatitis C - Annual Epidemiological Report for 2017
In 2017, 31 273 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases, 31 178 cases corresponds to a crude rate of 7.3 cases per 100 000 population.
Hepatitis C - Annual Epidemiological Report for 2015
In 2015, 34 651 cases of hepatitis C were reported from 28 EU/EEA Member States, a crude rate of 8.6 per 100 000 population. Of the cases reported, 1.0% were classified as acute, 12.7% as chronic, 69.5% as ‘unknown’ and 16.8% were not classified.
Communicable disease threats report Week 19, 5-11 May 2013
The ECDC communicable disease threats report is a weekly bulletin intended for epidemiologists and health professionals in the area of communicable disease prevention and control.
Hepatitis B and C epidemiology in selected population groups in the EU/EEA
The findings presented in this report will be part of the process of developing a European guidance for HBV and HCV testing and may provide support EU/EEA countries in the development of national guidelines and in the design and scale-up of testing interventions.
Hepatitis C - Annual Epidemiological Report 2016 [2014 data]
In 2014, 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States, a crude rate of 8.8 cases per 100 000 population.
Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA
This report gives an overview of chronic hepatitis B and C virus infection among foreign-born migrants in the EU/EEA.
Hepatitis B and C surveillance in Europe 2012
This is the second report on the enhanced surveillance of hepatitis B and C viral infections. It describes basic epidemiological features and trends of both diseases across countries in the EU/EEA for 2012.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
ECDC undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C (HBV/HCV) in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States.